Innoviva, Inc. (NASDAQ:INVA) insider Michael W. Aguiar sold 12,022 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $13.13, for a total value of $157,848.86. Following the completion of the transaction, the insider now directly owns 980,907 shares in the company, valued at approximately $12,879,308.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Innoviva, Inc. (NASDAQ INVA) traded up $0.11 on Tuesday, hitting $13.22. The stock had a trading volume of 848,089 shares, compared to its average volume of 1,045,006. Innoviva, Inc. has a 12-month low of $10.21 and a 12-month high of $14.87. The company has a debt-to-equity ratio of -2.59, a quick ratio of 6.71 and a current ratio of 6.71. The stock has a market cap of $1,420.00, a price-to-earnings ratio of 15.21 and a beta of 2.53.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.13). Innoviva had a net margin of 52.91% and a negative return on equity of 33.55%. The business had revenue of $48.64 million for the quarter, compared to analysts’ expectations of $57.18 million. During the same quarter in the prior year, the company posted $0.13 EPS. The business’s revenue for the quarter was up 46.0% on a year-over-year basis. research analysts forecast that Innoviva, Inc. will post 1.08 earnings per share for the current fiscal year.

Several research analysts recently issued reports on INVA shares. ValuEngine raised Innoviva from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Zacks Investment Research lowered Innoviva from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 16th. Cowen set a $16.00 target price on Innoviva and gave the stock a “buy” rating in a report on Monday, October 23rd. Morgan Stanley restated an “underweight” rating and set a $8.00 target price (up previously from $7.00) on shares of Innoviva in a report on Friday, October 6th. Finally, Deutsche Bank initiated coverage on Innoviva in a report on Monday, November 20th. They set a “hold” rating and a $13.00 target price for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $13.50.

Several institutional investors and hedge funds have recently modified their holdings of the company. Alps Advisors Inc. raised its stake in Innoviva by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 38,232 shares of the biotechnology company’s stock worth $489,000 after acquiring an additional 99 shares during the last quarter. Aperio Group LLC raised its stake in Innoviva by 2.0% in the 2nd quarter. Aperio Group LLC now owns 20,651 shares of the biotechnology company’s stock worth $264,000 after acquiring an additional 398 shares during the last quarter. Texas Permanent School Fund raised its stake in Innoviva by 1.0% in the 2nd quarter. Texas Permanent School Fund now owns 56,687 shares of the biotechnology company’s stock worth $726,000 after acquiring an additional 552 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in Innoviva by 4.0% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 18,300 shares of the biotechnology company’s stock worth $234,000 after acquiring an additional 710 shares during the last quarter. Finally, Profund Advisors LLC raised its stake in Innoviva by 8.8% in the 2nd quarter. Profund Advisors LLC now owns 15,220 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 1,227 shares during the last quarter. Hedge funds and other institutional investors own 74.44% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/05/insider-selling-innoviva-inc-inva-insider-sells-12022-shares-of-stock.html.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.